Urania Therapeutics (formerly RiboStruct) was created end of 2015 as a spinoff of IGBMC to leverage the expertise of Marat Yusupov & Gulnara Yusupova in the field of ribosome crystallography to develop new drugs.

Urania is developing readthrough compounds targeting the human ribosome following a structure-based drug design approach for the treatment of genetic diseases and some cancers caused by nonsense mutations.
Urania was granted by SATT Conectus an exclusive licence on the know-how developed in the Yusupov Lab.